US EditionBlood pressure drug boosts effectiveness of cancer therapy
Telmisartan uniquely boosts olaparib's effect by increasing tumor DNA damage and immune response, enabling trials for resistant prostate and ovarian cancers, Dartmouth researchers report.
6 Articles
6 Articles
Common blood pressure drug can boost cancer treatment
In a new Dartmouth Cancer Center (DCC) study led by clinical researcher Tyler J. Curiel, MD, MPH, FACP, investigators found that the FDA-approved blood pressure drug telmisartan can significantly enhance the cancer-killing activity of the targeted therapy olaparib, potentially expanding its use to many more patients. The findings are newly published in The Journal for ImmunoTherapy of Cancer.
Blood pressure drug boosts effectiveness of cancer therapy
In a new Dartmouth Cancer Center (DCC) study led by clinical researcher Tyler J. Curiel, MD, MPH, FACP, investigators found that the FDA-approved blood pressure drug telmisartan can significantly enhance the cancer-killing activity of the targeted therapy olaparib, potentially expanding its use to many more patients.
Common Blood Pressure Drug May Boost A Leading Cancer Therapy
A blood pressure medication sitting in millions of bathroom cabinets right now might help boost one of the most important classes of cancer drugs. The post Common Blood Pressure Drug May Boost A Leading Cancer Therapy appeared first on StudyFinds.
Coverage Details
Bias Distribution
- 60% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
